Table 1.
Patient and clinical characteristics separated by institution
| DFCI | JHU | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients N=224 | Without statin N=132 | Statin user N=92 | All patients N=270 | Without statin N=148 | Statin user N=122 | |||||||
| N | %, median (q1, q3) | N | %, median (q1, q3) | N | %, median (q1, q3) | N | %, median (q1, q3) | N | %, median (q1, q3) | N | %, median (q1, q3) | |
| PSA at diagnosis | 212 | 9.4 (5.0,30.5) | 124 | 9.7 (5.1,30.9) | 87 | 8.7 (4.6, 28.5) | 234 | 11.9 (6.3, 54) | 133 | 12.8 (6.5, 83.6) | 101 | 11.3 (6.3, 34) |
| Gleason score | ||||||||||||
| 6 or less | 34 | 15% | 19 | 14% | 15 | 16% | 16 | 6% | 10 | 7% | 6 | 5% |
| 7 | 70 | 31% | 41 | 31% | 29 | 32 | 71 | 26% | 36 | 24% | 35 | 29% |
| 8 or more | 110 | 49% | 65 | 49% | 45 | 49% | 152 | 56% | 85 | 57% | 67 | 55% |
| Unknown | 10 | 4% | 7 | 5% | 3 | 3% | 31 | 11% | 17 | 11% | 14 | 11% |
| T stage | ||||||||||||
| T1 | 137 | 61% | 77 | 58% | 59 | 64% | 33 | 12% | 15 | 10% | 18 | 15% |
| T2 | 44 | 20% | 26 | 20% | 18 | 20% | 63 | 23% | 36 | 24% | 27 | 22% |
| T3 | 17 | 8% | 11 | 8% | 6 | 7% | 102 | 38% | 54 | 36% | 48 | 39% |
| T4 | 2 | <1% | 2 | 2% | 0 | 0% | 11 | 4% | 8 | 4% | 5 | 4% |
| Tx/Unknown | 24 | 11% | 16 | 12% | 9 | 10% | 61 | 23% | 37 | 25% | 14 | 20% |
| N stage | ||||||||||||
| N0 | 85 | 38% | 51 | 39% | 33 | 36% | 152 | 56% | 77 | 52% | 75 | 61% |
| N1 | 28 | 13% | 20 | 15% | 8 | 9% | 64 | 24% | 38 | 26% | 26 | 21% |
| Nx/Unknown | 111 | 50% | 61 | 46% | 51 | 55% | 54 | 20% | 33 | 22% | 21 | 17% |
| M stage | ||||||||||||
| M0 | 97 | 43% | 59 | 45% | 38 | 41% | 177 | 66% | 91 | 61% | 86 | 70% |
| M1 | 37 | 17% | 26 | 20% | 10 | 11% | 78 | 29% | 50 | 34% | 28 | 23% |
| Mx/Unknown | 90 | 40% | 47 | 36% | 44 | 48% | 15 | 6% | 7 | 5% | 8 | 7% |
| Primary local | ||||||||||||
| RP+/-RT | 105 | 47% | 61 | 46% | 44 | 48% | 114 | 42% | 62 | 42% | 52 | 43% |
| RT | 61 | 27% | 30 | 23% | 31 | 34% | 67 | 25% | 30 | 20% | 37 | 30% |
| None/Unknown | 58 | 26% | 41 | 31% | 17 | 18% | 89 | 33% | 56 | 38% | 31 | 27% |
| Age at start of AA | 224 | 68 (62, 75) | 132 | 68 (61, 74) | 92 | 70 (64, 76) | 279 | 70 (64, 75) | 148 | 68 (62, 73) | 122 | 72 (67, 77) |
| Year at start of AA | ||||||||||||
| Prior to 2011 | 6 | 3% | 4 | 3% | 2 | 2% | 3 | 1% | 3 | 2% | 1 | 1% |
| 2011 | 38 | 17% | 21 | 16% | 17 | 18% | 64 | 24% | 43 | 29% | 21 | 17% |
| 2012 | 83 | 37% | 53 | 40% | 30 | 33% | 92 | 34% | 48 | 32% | 43 | 35% |
| 2013 | 56 | 25% | 30 | 23% | 26 | 28% | 78 | 29% | 39 | 26% | 39 | 32% |
| 2014–2015 | 41 | 18% | 24 | 18% | 17 | 18% | 33 | 12% | 15 | 10% | 18 | 15% |
| Mets at AA start | 215 | 96% | 126 | 95% | 89 | 97% | 258 | 96% | 141 | 95% | 117 | 96% |
| PSA at AA start | 205 | 20.1 (5.4, 56.2) | 121 | 20.3 (6.6, 70.6) | 84 | 16.9 (4.5, 55.1) | 266 | 34.5 (11.3, 103) | 145 | 33.1 (10.6, 126) | 121 | 35.6 (13, 80.1) |
| Sites of mets | ||||||||||||
| Bone and LN | 192 | 86% | 114 | 86% | 78 | 85% | 206 | 76% | 115 | 78% | 91 | 75% |
| Soft tissue | 23 | 10% | 12 | 9% | 11 | 12% | 52 | 19% | 26 | 18% | 26 | 21% |
| Statin use at AA start | 92 | 41% | 92 | 100% | 122 | 45% | 122 | 100% | ||||
| Prior use of enza | 16 | 7% | 10 | 8% | 6 | 7% | 17 | 6% | 4 | 3% | 13 | 11% |
| Prior use of doce. | 59 | 26% | 35 | 27% | 24 | 26% | 79 | 29% | 49 | 33% | 30 | 25% |
*
AA: abiraterone acetate; Mets: metastases; LN: lymph node; Enza: enzalutamide; Doce: docetaxel